---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-252153"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:44:00.895222+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio reports Q3 net loss of $41.2M, submits NDA for taletrectinib in ROS1+ NSCLC

## Summary
- Net loss of $41.2M ($0.15 per share) vs $19.6M ($0.09) in Q3 2023; cash of $549.1M at Sept 30.
- NDA for taletrectinib submitted to FDA for line-agnostic full approval in advanced ROS1+ NSCLC; potential launch mid-2025.
- Pooled Phase 2 data: 89% ORR in TKI-naïve patients, median DOR 44 months and PFS 46 months; low 7% discontinuation rate.
- Appointed Philippe Sauvage as CFO in October; David Hung appointed Chairman, Robert Bazemore lead independent director.
- R&D expenses $27.7M (up $9.2M YoY); G&A $19.6M (up $11.8M YoY) driven by AnHeart acquisition costs.

## SEC filing metadata
- accession: 0001193125-24-252153
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312524252153/0001193125-24-252153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312524252153/d826537d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-252153
- JSON: https://secwatch.observer/filing/0001193125-24-252153.json
- Plain text: https://secwatch.observer/filing/0001193125-24-252153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.